Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2025-06-17 00:00:00 ET · period of report 2025-06-13 · accession 0001610717-25-000236 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-17 | 2025-06-13 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | +37.5K | 236.9K | +19% | $0 |
| DM | 2025-06-17 | 2025-06-13+ | CTMX | Ogden Christopher | CFO | S - Sale+OE | $2.72 | -12.3K | 199.4K | -6% | -$33.4K |
| D | 2025-06-17 | 2025-06-13 | CTMX | Ogden Christopher | CFO | M - OptEx | $0.00 | -37.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-13 | M | A | 37,500 | $0.00 | 236,885 | D | — | — | (F2) Includes 149,987 RSUs. |
| 2 | Common | Common Stock | 2025-06-16 | S | D | 10,614 | $2.69 | 226,271 | D | — | — | (F2) Includes 149,987 RSUs. |
| 3 | Common | Common Stock | 2025-06-13 | S | D | 1,641 | $2.95 | 199,385 | D | — | — | (F2) Includes 149,987 RSUs. |
| 4 | Derivative | Performance Stock Units | 2025-06-13 | M | D | 37,500 | $0.00 | 0 | D | — · — to — | 37,500 Common Stock | (F5) Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. |